FibroGen (NASDAQ: FGEN) experienced a significant after-hours surge of 22.22%, trading around $10.23, up from the day’s end price of $8.37.
This increase follows the company’s Q2 financial report, where it posted a loss of $1.88 per share, surpassing the anticipated $2.25 loss. Despite better-than-expected earnings, revenue fell to $1.35 million, significantly missing the $2.63 million forecast and marking a sharp decline from last year’s $50.64 million.
Today’s trading saw FGEN move between a low of $8.37 and a high of $10.23, with a volume of 121,000 shares.
